VIVORYON THERAPEUTICSCS Action · NL00150002Q7 · A2QJV6 (LSSI) — cotations en temps réel, données d'entreprise, dividendes, fondamentaux et analyse de portefeuille IA sur MoneyPeak

Aperçu

Analyse alimentée par l’IA

Analyse fondamentale

Découvrez ce que disent vraiment les chiffres — avant le marché

Analyser maintenant

Sentiment des actualités

Les actualités d’aujourd’hui sont-elles un signal d’achat ou un avertissement ?

Analyser maintenant

Acheter / Conserver / Vendre

Faut-il acheter, conserver ou vendre ? Obtenez l’avis de l’IA dès maintenant.

Analyser maintenant

Évaluation des risques

Détectez les risques cachés avant qu’ils n’impactent votre portefeuille.

Analyser maintenant

Juste valeur

Cette action est-elle bon marché, correctement valorisée ou surévaluée ?

Analyser maintenant

Dernières analyses d’IA sur VIVORYON THERAPEUTICSCS

Pas de cours

30.04.2026 15:35

Cours actuels de VIVORYON THERAPEUTICSCS

Bourse	Ticker	Devise	Dernier échange	Cours	Variation journalière
EURONEXT - EURONEXT AMSTERDAM	VVY.AS	EUR	30.04.2026 15:35	1,31 EUR	0,005 EUR +0,38 %
London	0R3M.L	EUR	30.04.2026 14:14	1,31 EUR	0,01 EUR +0,77 %
Düsseldorf	VTNVAEQ7.DUSB	EUR	30.04.2026 06:11	1,33 EUR	-
Hamburg	VTNVAEQ7.HAMB	EUR	30.04.2026 06:07	1,33 EUR	-
Quotrix	VTNVAEQ7.DUSD	EUR	30.04.2026 05:27	1,33 EUR	-

Profil de l'entreprise pour VIVORYON THERAPEUTICSCS Action

Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a small molecule QC inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease; and for the treatment of cancer. Its preclinical development product is PQ1565, a small molecule glutaminyl-peptide cyclotransferase-like inhibitor for the treatment of cancer. In addition, the company is developing a monoclonal antibody targeting pGlu-Abeta to enhance its clearance. Vivoryon Therapeutics N.V. has a research collaboration agreement with University Medical Center Schleswig-Holstein to discover and develop therapeutics in cancer immunotherapy; collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.